Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCLNASDAQ:DAWNNASDAQ:GOSSNASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$2.57-1.2%$2.46$1.89▼$4.34$765.83M0.52.66 million shs2.98 million shsDAWNDay One Biopharmaceuticals$7.74-2.0%$8.44$6.41▼$18.07$784.48M-1.241.07 million shs729,054 shsGOSSGossamer Bio$0.96-2.1%$1.11$0.50▼$1.55$217.75M1.881.58 million shs2.46 million shsQUREuniQure$14.18-0.6%$11.92$3.73▼$19.18$766.81M0.421.77 million shs646,241 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics+2.77%+7.44%+2.77%-25.29%-33.33%DAWNDay One Biopharmaceuticals+6.18%+15.50%-4.59%-35.30%-47.99%GOSSGossamer Bio+9.43%+16.57%-23.50%+5.29%+38.25%QUREuniQure-0.90%+9.69%-0.70%-9.00%+212.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics2.4918 of 5 stars3.31.00.00.03.33.30.6DAWNDay One Biopharmaceuticals2.4101 of 5 stars4.60.00.00.02.42.50.0GOSSGossamer Bio3.7616 of 5 stars3.52.00.04.72.71.70.0QUREuniQure2.3269 of 5 stars3.42.00.00.02.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.67Moderate Buy$7.50191.83% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$32.29317.13% UpsideGOSSGossamer Bio 3.00Buy$7.50682.64% UpsideQUREuniQure 2.82Moderate Buy$38.80173.62% UpsideCurrent Analyst Ratings BreakdownLatest GOSS, QURE, ABCL, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/17/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/16/2025ABCLAbCellera BiologicsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$4.00 ➝ $5.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/1/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$27.00 ➝ $38.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.003/18/2025GOSSGossamer BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/14/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.003/5/2025DAWNDay One BiopharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$39.00 ➝ $34.003/4/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.003/3/2025ABCLAbCellera BiologicsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$28.83M26.56N/AN/A$3.97 per share0.65DAWNDay One Biopharmaceuticals$131.16M5.98N/AN/A$3.98 per share1.94GOSSGossamer Bio$114.70M1.90N/AN/A$0.28 per share3.42QUREuniQure$27.12M28.28N/AN/A$4.34 per share3.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$146.40M-$0.55N/AN/AN/A-533.32%-15.73%-12.22%5/8/2025 (Estimated)DAWNDay One Biopharmaceuticals-$188.92M-$1.08N/AN/AN/AN/A-22.40%-19.79%5/6/2025 (Estimated)GOSSGossamer Bio-$179.82M-$0.26N/AN/AN/AN/A-127.28%-22.12%5/6/2025 (Estimated)QUREuniQure-$308.48M-$4.93N/AN/AN/A-837.80%-188.82%-32.17%5/6/2025 (Estimated)Latest GOSS, QURE, ABCL, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ABCLAbCellera Biologics-$0.17N/AN/AN/A$7.12 millionN/A5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.45N/AN/AN/A$30.28 millionN/A5/6/2025Q1 2025GOSSGossamer Bio-$0.19N/AN/AN/A$3.95 millionN/A5/6/2025Q1 2025QUREuniQure-$1.07N/AN/AN/AN/AN/A3/18/2025Q4 2024GOSSGossamer Bio-$0.15-$0.15N/A-$0.15$7.02 million$9.38 million2/25/2025Q4 2024DAWNDay One Biopharmaceuticals-$0.35-$0.69-$0.34-$0.69$27.11 million$29.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A9.349.34DAWNDay One BiopharmaceuticalsN/A14.6214.55GOSSGossamer Bio3.646.746.74QUREuniQure0.926.516.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%DAWNDay One Biopharmaceuticals87.95%GOSSGossamer Bio81.23%QUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.00%DAWNDay One Biopharmaceuticals8.40%GOSSGossamer Bio5.00%QUREuniQure4.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500297.99 million212.66 millionOptionableDAWNDay One Biopharmaceuticals60101.35 million92.38 millionOptionableGOSSGossamer Bio180227.22 million215.27 millionOptionableQUREuniQure50054.08 million46.43 millionOptionableGOSS, QURE, ABCL, and DAWN HeadlinesRecent News About These CompaniesuniQure (NASDAQ:QURE) Given Buy Rating at HC WainwrightApril 22 at 2:47 AM | americanbankingnews.comuniQure (NASDAQ:QURE) Receives $38.80 Average Price Target from AnalystsApril 22 at 2:05 AM | americanbankingnews.comuniQure (QURE) Moves 38.5% Higher: Will This Strength Last?April 21, 2025 | zacks.comuniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A HoldApril 21, 2025 | seekingalpha.comuniQure (NASDAQ:QURE) Short Interest Up 43.9% in MarchApril 20, 2025 | americanbankingnews.comuniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's DiseaseApril 17, 2025 | globenewswire.comUniQure (QURE) Reports Q4 Loss, Misses Revenue EstimatesFebruary 27, 2025 | zacks.comuniQure Announces 2024 Financial Results and Highlights Recent Company ProgressFebruary 27, 2025 | globenewswire.comuniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four YearsFebruary 7, 2025 | benzinga.comCSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia BFebruary 7, 2025 | prnewswire.comuniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseFebruary 3, 2025 | globenewswire.comuniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALSJanuary 30, 2025 | globenewswire.comuniQure Announces Pricing of its Public OfferingJanuary 8, 2025 | globenewswire.comuniQure Announces Proposed Public OfferingJanuary 7, 2025 | globenewswire.comUp 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?December 15, 2024 | fool.comQURE Soars on FDA Alignment for Speedy Approval of Huntington's DrugDecember 11, 2024 | zacks.comuniQure's AMT-130: A Bold Step For Huntington's, But Not Without HurdlesDecember 10, 2024 | seekingalpha.comuniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's DiseaseDecember 10, 2024 | globenewswire.comWall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a BetNovember 29, 2024 | zacks.comWhat Makes uniQure (QURE) a New Buy StockNovember 28, 2024 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGOSS, QURE, ABCL, and DAWN Company DescriptionsAbCellera Biologics NASDAQ:ABCL$2.57 -0.03 (-1.15%) Closing price 04:00 PM EasternExtended Trading$2.58 +0.02 (+0.58%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Day One Biopharmaceuticals NASDAQ:DAWN$7.74 -0.16 (-2.03%) Closing price 04:00 PM EasternExtended Trading$7.74 0.00 (-0.06%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Gossamer Bio NASDAQ:GOSS$0.96 -0.02 (-2.13%) Closing price 04:00 PM EasternExtended Trading$0.96 0.00 (-0.03%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.uniQure NASDAQ:QURE$14.18 -0.08 (-0.56%) Closing price 04:00 PM EasternExtended Trading$13.99 -0.19 (-1.34%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
